Ultra low dose oral contraceptives with sustained efficacy...

Details Ultra low dose oral contraceptives with sustained efficacy... Ultra low dose oral contraceptives with sustained efficacy...

A - Human Necessities

61

K

A61K 31/565 (2006.01)

Patent

CA 2392841

A method of female contraception involves administering a combination of estrogen and progestin continuously for more than a year in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include lack of menstrual bleeding, less patient anemia, less total exposure to medication when compared to a 35 microgram (low dose) containing oral contraceptive, reduced risk of endometrial cancer, higher compliance rates and more lifestyle convenience for patients who desire less uterine bleeding each year or longer.

Affiliated with

Also associated with

Rating

Ultra low dose oral contraceptives with sustained efficacy... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ultra low dose oral contraceptives with sustained efficacy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ultra low dose oral contraceptives with sustained efficacy... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1432727